[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"marfan-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:marfan-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,54,81,109,132,159,194,216,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":38,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055",false,"NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)","ALL",{"count":18,"type":19},1211,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[39,40],"hereditary cardiovascular diseases","whole genome sequencing","RECRUITING","2026-05-04",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":45},"2025-04-30",{"date":49,"type":19},"2026-08-31",{"name":51,"class":52},"Hospital do Coracao","OTHER",27,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100631022","nutritional-ketosis-marfan-100631022","NCT07495267","Nutritional Ketosis Marfan","Nutritional Ketosis as a Novel Therapeutic Strategy to Stabilize Chronic Aortic Dissection in Marfan Syndrome","Inclusion Criteria:\n\n1. Adults between 18 and 50 years old.\n2. Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document.\n3. Genetically or clinically confirmed Marfan syndrome\n4. Chronic descending thoracic aortic dissection present for at least three months\n5. Maximal descending thoracic aortic diameter must measure between 4.0 and 5.0 cm at baseline on contrast-enhanced computed tomography angiography (CTA)\n6. Have been clinically stable and consistent antihypertensive regimen for at least four weeks\n\nExclusion Criteria:\n\n1. Acute or rapidly enlarging dissection (\\>0.5 cm increase over the preceding three months)\n2. Prior descending thoracic aortic repair or endograft placement\n3. Advanced renal or hepatic dysfunction\n4. Poorly controlled diabetes requiring insulin\n5. Active malignancy, pregnancy, or other metabolic or nutritional disorders that would contraindicate ketogenic therapy\n6. Body mass index below 18 kg\u002Fm²\n7. Inability to comply with dietary restrictions or follow-up imaging\n8. Current enrollment in another interventional study, which in the opinion of the principal investigator, may confound study results.\n9. Patients who, in the opinion of the principal investigator, are not suitable candidates for study participation.","18 Years","50 Years",{"count":64,"type":19},15,"INTERVENTIONAL",[67],"NA","In this pilot clinical trial, the investigators will test whether a carefully supervised ketogenic diet can safely help people with Marfan syndrome who already have a chronic or residual aortic dissection. Fifteen participants will work with a study coordinator and dietitian to learn how to follow the diet and will have regular guidance and check-ins. The participants will measure their blood ketone levels at home with a simple finger-stick device and relay their readings to the research team. Every three months, blood samples will also be collected to confirm the body's level of ketosis.\n\nParticipants will continue their usual heart and blood-pressure medicines and regular visits with their doctors. Standard of care computed tomography (CT) scans of the aorta will be performed at the start of the study and then again at 6 and 12 months to see if the aorta changes in size.\n\nThe main goal is to see how many patients can avoid needing aortic surgery within one year, compared with what is normally expected from past studies. The investigators will also track how well patients follow the diet, how their aorta changes, and whether inflammation in their blood decreases.",[30,70],"Aortic Dissection","NOT_YET_RECRUITING","2026-03-22",{"date":74,"type":45},"2026-03-27",{"date":76,"type":19},"2026-03-13",{"date":78,"type":19},"2028-03-01",{"name":80,"class":52},"Washington University School of Medicine",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100436991","biological-collection-for-marfan-and-related-syndromes-100436991","NCT04970459","Biological Collection for Marfan and Related Syndromes","Constitution of a Biological Collection to Study the Pathophysiology in Marfan Syndrome and Related Syndromes and to Identify Predictive Factors of Disease Progression","MARFANS","Inclusion Criteria:\n\n* Children aged at least 3 years old or adult with Marfan syndrome or related syndromes\n* Patients affiliated to or beneficiaries of a social security scheme\n* Patients able to receive information on the progress of the study and understand the information form to participate in the study. That implies to master the French language and not to be subject to a restriction of rights by the judicial authorities\n* Patients or legal representative who have given their consent to participate in the study (expression of no objection)\n\nExclusion Criteria:\n\n* Patients subject to a legal protection measure (guardianship, curators, or safeguard of justice)\n* Pregnant or breastfeeding women","3 Years","99 Years",{"count":92,"type":19},300,"The present study will establish a collection of biological samples from Marfan patients or with associated diseases to be used for research purposes only, with due respect for confidentiality.",[30],[96,97,98],"Biological collection","Marfan syndrome","Marfan associated syndromes","2026-03-16",{"date":101,"type":45},"2026-03-17",{"date":103,"type":45},"2022-01-24",{"date":105,"type":19},"2031-08-07",{"name":107,"class":52},"University Hospital, Toulouse",1,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":65,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":108},"100503667","adapted-physical-activity-program-apa-for-effort-rehabilitation-of-children-and-teenagers-with-marfan-syndrome-100503667","NCT05838235","Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome","Marfan&Moves (M&M's) : an Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Marfan Syndrome: an Interventional, Prospective, Monocentric Study.","M&M's","Inclusion Criteria:\n\n* Genetically confirmed Marfan syndrome or related syndrome\n* Girl or boy aged 7 to 17\n* Informed and written consent signed by at least one of the two holders of parental authority\n* Patient affiliated to a social security scheme or equivalent\n\nExclusion Criteria:\n\n* Cardiac contraindications to the APA program:\n\n  * Severe aortic dilation (aortic diameter \\> 45 mm)\n  * and\u002For left ventricular failure (left ventricular ejection fraction \\\u003C45%)\n  * and\u002For severe mitral leakage ≥ grade 3\n* Pregnancy","7 Years","17 Years",{"count":120,"type":19},30,[67],"This research study aims to evaluate the effect of a 6-month adapted physical activity program (APA) on the endurance capacities (evaluated as the maximum oxygen consumption \\[VO2 peak\\] on a cardiopulmonary exercise test) of children and adolescents with Marfan syndrome or related.",[30],"2026-03-02",{"date":126,"type":45},"2026-03-03",{"date":128,"type":45},"2023-04-24",{"date":130,"type":19},"2028-10",{"name":107,"class":52},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":108},"100625188","clinical-and-psychosocial-factors-associated-with-physical-activity-level-in-adults-with-marfan-syndrome-100625188","NCT07419386","Clinical and Psychosocial Factors Associated With Physical Activity Level in Adults With Marfan Syndrome","Clinical and Psychosocial Factors Associated With Physical Activity Level in Adults With Marfan Syndrome: A Cross-Sectional Observational Study","Inclusion Criteria:\n\n* Adults (≥18 years).\n* A confirmed diagnosis of Marfan syndrome according to accepted clinical criteria used in routine follow-up.\n* Ability to understand and complete an online questionnaire in Spanish.\n* Access to the internet and an appropriate device to complete the survey.\n* Provision of informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment or comprehension\u002Fliteracy difficulties that preclude valid completion of the questionnaires.\n* Who have experienced a major cardiovascular event or undergone recent cardiovascular\u002Faortic surgery that substantially limits physical activity during the most recent reference period (e.g., within the past 3 months).\n* With acute conditions or recent musculoskeletal injuries not attributable to Marfan syndrome that markedly restrict physical activity during the previous 7 days (the reference period of the IPAQ-SF).\n* With incomplete questionnaires for essential variables (IPAQ-SF and\u002For main predictors)",{"count":140,"type":19},118,"Background. Marfan syndrome is a genetic connective tissue disorder with cardiovascular and musculoskeletal involvement. Despite clinical advances, many patients exhibit low levels of physical activity, influenced by clinical and psychosocial factors such as fear of exertion, fatigue, or pain. Physical activity behavior in this population remains insufficiently characterized.\n\nObjective. To assess the level of physical activity in adults with Marfan syndrome and to identify the main associated clinical and psychosocial factors, in order to determine predictors of low physical activity.\n\nMethods. An observational, analytical, cross-sectional study will be conducted. Adults with a diagnosis of Marfan syndrome will be included. The primary outcome will be physical activity level, assessed using the International Physical Activity Questionnaire-Short Form. The main independent variables will include kinesiophobia (Tampa Scale for Kinesiophobia), physical activity self-efficacy, perceived fatigue (Fatigue Severity Scale), musculoskeletal pain (Brief Pain Inventory-Short Form), and cardiovascular clinical factors. Potential confounders will include age, sex, body mass index, time since diagnosis, medical recommendations regarding exercise, and current pain. Descriptive analyses and a multivariable logistic regression model will be performed to identify independent predictors of low physical activity.\n\nExpected results. To characterize the level of physical activity in adults with Marfan syndrome and to identify the clinical and psychosocial factors that independently predict low physical activity in this population.",[30],[97,144,145,146,147,148,149],"Motor activity","Exercise","Kinesiophobia","Fatigue","Pain","Self efficacy","2026-02-11",{"date":152,"type":45},"2026-02-19",{"date":154,"type":19},"2026-02-22",{"date":156,"type":19},"2026-05-26",{"name":158,"class":52},"University of Oviedo",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":65,"phases":168,"briefSummary":169,"conditions":170,"keywords":177,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":108},"100213022","complex-aortic-aneurysm-repair-using-physician-modified-endografts-and-custom-made-devices-100213022","NCT02050113","Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices","CARPE-CMD","Inclusion Criteria:\n\n* A patient may be suitable for inclusion in the study if the patient has at least one of the following:\n\n  1. Aortic or aortoiliac aneurysm with diameter ≥5.5 cm\n  2. Aortic or aortoiliac aneurysm with a history of growth ≥1.0 cm per year, or clinical indication for aneurysm repair based on symptoms\n\n     General Inclusion Criteria\n\n  \u003C!-- -->\n\n  1. Cannot be treated with a currently available non-modified approved device\n  2. Symptomatic on presentation and unsafe to wait for the time necessary to obtain a currently available non-modified approved device\n  3. At least 18 years of age\n  4. Not pregnant or breastfeeding\n  5. Willing and able to comply with five years of follow-up\n  6. Willing and able to provide informed consent prior to enrollment\n  7. No systemic or local infection that may increase the risk of endovascular graft infection\n  8. High risk for open surgical repair based on any of the factors below:\n\n     a. Anatomic i. Previous abdominal surgery ii. Previous left-sided thoracotomy (if the proposed open repair would require dissection of the thoracic aorta) iii. Previous aortic surgery b. Physiologic i. ASA Category III or higher ii. Age \\>70 years iii. Previous myocardial infarction, coronary artery disease, or coronary artery stent iv. Coronary stress test with a reversible perfusion defect v. Congestive heart failure vi. COPD\n\n     Exclusion Criteria:\n* Exclusion Criteria Medical Exclusion Criteria\n\n  1. Cultural objection to receipt of blood or blood products\n  2. Allergy or sensitivity to stainless steel, polyester, polypropylene, solder (tin, silver), gold, or nitinol\n  3. Anaphylactic reaction to contrast that cannot be adequately pre-medicated\n  4. Uncorrectable coagulopathy\n  5. Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)\n  6. Patient has active malignancy with life expectancy of less than 2 years\n  7. Patient has life expectancy less than two years\n\nAnatomical Exclusion Criteria\n\n1. Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access\n2. Proximal neck length ≤25 mm\n3. Proximal neck, measured outer wall to outer wall on a sectional image (CT)\n\n   1. For use of Zenith Flex: diameter \\>32 mm or \\\u003C18 mm\n   2. For use of Zenith TX2: diameter \\>38 mm or \\\u003C24 mm (for proximal and distal neck diameter)\n4. Proximal neck angulated more than 60 degrees relative to the long axis of the aneurysm\n5. Proximal neck diameter change over the length of the proximal seal zone \\>4 mm\n6. Proximal seal site with a circumferential thrombus\u002Fatheroma\n7. Iliac artery diameter, measured inner wall to inner wall on a sectional image (CT) \\\u003C7.0 mm at any point along access length (prior to deployment)\n8. Ipsilateral iliac artery fixation site diameter, measured inner wall on a sectional image (CT) \\>21 mm at distal fixation site\n9. Iliac artery distal fixation site \\\u003C10 mm in length\n10. Non-bifurcated segment of any artery to be stented \\\u003C 15 mm in length\n11. Artery to be stented with a maximum diameter \\\u003C3 mm or \\>10 mm at the vessel ostium\n12. Inability to maintain at least one patent hypogastric artery",{"count":167,"type":19},600,[67],"The purpose of this study is to evaluate the safety and efficacy of custom made devices, Zenith t-Branch devices and physician modification of FDA approved off-the-shelf endovascular grafts in the treatment of patients with complex abdominal aneurysms, aortoiliac aneurysms, thoracoabdominal aneurysms and aortic arch aneurysms who (1) have anatomy not suitable for endovascular repair using grafts currently marketed in the United States,(2) are deemed unsafe to wait the required time necessary for commercial endograft manufacturing, and (3) are at high risk for open surgical repair. Amendment to the study has created a cohort open to people with connective tissue diseases such as Marfan, Ehlers-Danlos or Loey-Dietz syndromes to enroll in the trial. An additional amendment to the study allows the use of a custom made device to treat an aneurysm in the aortic arch.",[171,172,173,174,30,175,32,176],"Complex Aortic Aneurysms","Thoracoabdominal Aneurysms","Pararenal Aneurysms","Juxtarenal Aneurysms","Ehlers-Danlos Syndrome","Aortic Arch Aneurysm",[171,172,178,179,180,181,182,183,70,184],"Pararenal Aortic Aneurysms","Juxtarenal Renal Aneurysms","Endovascular Branch Graft","Fenestrated Stent Graft","Abdominal Aortic Aneurysm","Endovascular","Aortic Arch Aneurysms","2025-10-20",{"date":187,"type":45},"2025-10-22",{"date":189,"type":4},"2014-03",{"date":191,"type":19},"2030-03",{"name":193,"class":52},"Andres Schanzer",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100605986","multicentre-longitudinal-study-of-bone-mineralisation-characteristics-in-marfan-syndrome-and-ehlers-danlos-syndrome-100605986","NCT07169669","Multicentre Longitudinal Study of Bone Mineralisation Characteristics in Marfan Syndrome and Ehlers-Danlos Syndrome","BONE","Inclusion Criteria:\n\n* Subjects with Marfan syndrome and Ehlers-Danlos syndrome according to the revised reference criteria belonging to the Cardiovascular genetic center at IRCCS Policlinico San Donato and the Reference Centre for Ehlers-Danlos Syndromes Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico;\n* Adult and paediatric subjects who have performed at least one Bone Mineral Densitometry within the observation period of the study.\n\nExclusion Criteria:\n\n* Presence of prostheses in the spinal column;\n* Presence of prostheses in the coxofemoral joint;\n* Oncological bone diseases reported in history.",{"count":202,"type":19},150,"The general objective of this research is to evaluate the characteristics of bone mineralisation in patients with Marfan syndrome or Ehlers-Danlos syndrome on a large case series.\n\nIn particular we intend to obtain data regarding the characteristics of bone mineralisation, as well as their variation over time and the relationships existing with other clinical-anamnestic parameters, in patients with Marfan syndrome or Ehlers-Danlos syndrome by retrospectively analysing (data already collected for normal clinical practice and already available at the hospital) the case history of the Cardiovascular genetic center at IRCCS Policlinico San Donato and the related Computerized Bone Mineralometry (MOC) examinations performed at the Radiology Service of the same hospital between 1 September 2019 and 31 December 2022.",[30,205,206],"Ehlers-Danlos Syndrome (EDS)","Mineral Density","2025-09-04",{"date":209,"type":45},"2025-09-12",{"date":211,"type":19},"2025-10-31",{"date":213,"type":19},"2026-05-31",{"name":215,"class":52},"IRCCS Policlinico S. Donato",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":108},"100493232","marfan-syndrome-mfs-and-facial-dysmorphism-non-invasive-3d-assessment-100493232","NCT05702476","Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment","FACE","Inclusion Criteria:\n\n* White european ethnicity;\n* Signed informed consent;\n\nExclusion Criteria:\n\n* Previous relevant traumas affecting the craniofacial district or maxillofacial surgery;\n* Presence of beard and mustache;\n* Pregnancy",{"count":224,"type":19},140,"The goal of this study observational prospective study is to define the facial morphological features associated with Marfan syndrome (MFS). The main qustion it aims to answer are:\n\n1. To describe the facial morphological features associated with MFS and their evolution over time;\n2. To study the association between facial morphology and the features of reference for the diagnosis of MFS.",[227,30],"Rare Diseases",[227,97,229],"Facial features","2025-01-09",{"date":232,"type":45},"2025-01-13",{"date":234,"type":45},"2023-01-09",{"date":236,"type":19},"2027-06",{"name":215,"class":52},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":65,"phases":249,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":108},"100501443","marfan-syndrome-moderate-exercise-trial-ii-100501443","NCT05809323","Marfan Syndrome Moderate Exercise Trial II","Clinical Trial On The Effects Of Moderate Physical Activity On Health And Well-Being In Adolescents And Young Adults With Marfan Syndrome","Inclusion Criteria:\n\n* Male and female patients diagnosed with Marfan syndrome (defined by Ghent criteria and either a pathogenic variant in FBN1 or ectopia lentis)\n* Age 10-25 years at enrollment\n\nExclusion Criteria:\n\n1. History of aortic surgery\n2. History of spinal surgery with implanted materials that may negatively impact MRI safety or imaging quality.\n3. Diagnosis of major congenital heart disease (ASD, VSD, bicuspid aortic valve, and mitral valve prolapse will not qualify as exclusion criteria)\n4. Condition limiting the ability to perform moderate exercise.\n5. Major concurrent diagnosis that may confound the interpretation of the effect of the proposed intervention on the proposed outcome measures.\n6. Aortic dilation meeting threshold for prophylactic aortic surgical intervention (\\>\u002F= 4.5 cm in diameter)","10 Years","25 Years",{"count":248,"type":19},50,[67],"Marfan syndrome (MFS) is a distinctive connective tissue disorder that affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities. The lack of exercise and deconditioning have detrimental effects including increasing weakness, joint pain, decreased endurance, and depressive symptoms. Given the significant paucity of data currently existing on the effects of exercise in humans with MFS, and the recent, optimistic findings in rodent models, this pilot trial was established to assess the effects of moderated dynamic exercise in adolescents and young adults with MFS.",[30],[253,254,255],"Cardiovascular","Moderate Exercise","Physical Therapy","2024-01-23",{"date":258,"type":45},"2024-01-24",{"date":260,"type":45},"2023-09-01",{"date":262,"type":19},"2027-07-01",{"name":264,"class":52},"Baylor College of Medicine"]